Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Share-based Compensation (2020 - 2025)

BioAtla's Share-based Compensation history spans 6 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 116.73% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $5.4 million, up 1748.3%, while the annual FY2025 figure was $5.4 million, 1748.3% up from the prior year.
  • Share-based Compensation reached $1.1 million in Q4 2025 per BCAB's latest filing, down from $1.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $12.3 million in Q2 2021 to a low of -$6.7 million in Q4 2024.
  • Average Share-based Compensation over 5 years is $2.9 million, with a median of $3.5 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: soared 155.6% in 2021, then tumbled 344.56% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $3.8 million in 2021, then decreased by 8.11% to $3.5 million in 2022, then decreased by 21.79% to $2.7 million in 2023, then crashed by 344.56% to -$6.7 million in 2024, then soared by 116.73% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for BCAB's Share-based Compensation are $1.1 million (Q4 2025), $1.3 million (Q3 2025), and $1.4 million (Q2 2025).